Danish drug maker Novo Nordisk is launching its once-daily Wegovy pill in the United States.
It is offering 1.5 milligram and 4mg doses at $US149 ($A223) per month for self-paying patients from Monday in an intensely competitive weight-loss drug market.
Subscribe for FREE to the HealthTimes magazine
The pill was approved by the US Food and Drug Administration last month, a boon to Novo Nordisk as it looks to regain ground lost to US rival Eli Lilly.
Lilly awaits US approval for its weight-loss pill, possibly by March.
The Wegovy pill could attract new consumers as Novo looks to revive its fortunes after profit warnings and sliding shares last year.
FEATURED JOBS
Integral Diagnostics (IDX)
Integral Diagnostics (IDX)
The pill offers more flexibility and an alternative for those who dislike needles used in injectable medication.
Shares of the Danish drug maker rose more than 2.0 per cent in late morning trading.
Lilly shares fell about 1.0 per cent in US pre-market trading.
A key part to success for the pill will be attracting cash-paying consumers who cannot get insurance coverage, a stark shift from the dominant business model where drug pricing is managed through health insurance plans.
The low 1.5mg dose is the starter dose for the Wegovy pill, which is made up of semaglutide - the same active ingredient found in its blockbuster injectable weight loss and diabetes treatments - marketed under the brand names Wegovy and Ozempic.
Novo also offers the 1.5mg starter dose for its oral semaglutide drug for type 2 diabetes, sold as Rybelsus.
Novo's pill will also be sold in 9mg and a higher long-term dose of 25mg.
The drug maker's website showed that the two higher doses will be priced at $US299 for a month's supply, while the 4mg dose will rise to $US199 from April 15.
Lilly plans to cap higher doses of its obesity pill, if approved, at $US399 a month for repeat cash buyers.
Lilly's injectable drug Zepbound has largely been ahead of Novo's Wegovy in weekly US prescriptions over the past year.
US list prices for the injectables are about $US1000 per month or more.
Both companies have reduced prices of their injectables for customers paying in cash rather than using health insurance.
Novo began selling its Wegovy injection at $US349 a month to cash payers in November.
Under a deal with US President Donald Trump, Novo and Lilly also agreed to offer starter doses of their weight-loss pills at $US149 per month for Medicare and Medicaid enrollees, and to cash payers via the White House's new direct-to-consumer TrumpRx site, which is expected to be launched this month.
Novo's injectable drugs, which belong to a class of treatments known as GLP-1s, have drawn unprecedented demand in recent years, which led to supply constraints in 2024.
Ahead of the pill launch, Novo said it was manufacturing the pill in North Carolina and has been building supplies for some time.
